Literature DB >> 2480626

Reproducibility of refraction and visual acuity measurement under a standard protocol. The Macular Photocoagulation Study Group.

D W Blackhurst1, M G Maguire.   

Abstract

The authors present results of a study in which certified visual acuity examiners in the Macular Photocoagulation Study Group, performed independent replicate refractions and visual acuity measurements on both eyes of patients whose visual acuities ranged from 20/20 to less than 20/800. Patients with neovascular age-related macular degeneration (AMD), ocular histoplasmosis, or idiopathic neovascularization were represented. A total of 328 observations for 164 eyes from 82 patients were available for analysis. Overall reliabilities of the refraction data and the visual acuity data were 98.9% and 98.7%, respectively. Differences between replicate measurements were small; 87% were less than one line. However, differences were greater in patients with visual acuity less than 20/100 and in patients with AMD. These results indicate that the reliability of refraction and visual acuity measurements under a standard protocol is high and may depend on both visual acuity level and disease process. If a standard, systemic procedure is used for refraction and visual acuity testing, the clinician may be able to differentiate between true changes and measurement error, even among low vision patients with AMD.

Entities:  

Mesh:

Year:  1989        PMID: 2480626

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  19 in total

1.  Intravitreal triamcinolone acetonide for exudative age related macular degeneration.

Authors:  D Wong; I Campbell; C Groenwald; E Lancaster
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

2.  Repeatability of visual function measures in age-related macular degeneration.

Authors:  Tariq Aslam; Sajjad Mahmood; Konstantinos Balaskas; Niall Patton; Rajeev G Tanawade; Shi Zhuan Tan; Stephen A Roberts; Jeremy Parkes; Paul N Bishop
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-07-25       Impact factor: 3.117

3.  Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome.

Authors:  Heinrich Gerding; Vlassios Loukopoulos; Juliane Riese; Lars Hefner; Melanie Timmermann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-09       Impact factor: 3.117

4.  Visual acuity testing in schools: what needs to be done.

Authors:  Y F Yang; M D Cole
Journal:  BMJ       Date:  1996-10-26

5.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

6.  Assessment of retinal layers and visual rehabilitation after epiretinal membrane removal.

Authors:  Jae Hui Kim; Se Woong Kang; Min Gui Kong; Hyo Shin Ha
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-09       Impact factor: 3.117

7.  Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography.

Authors:  Elizabeth A Sugar; Douglas A Jabs; Michael M Altaweel; Sue Lightman; Nisha Acharya; Albert T Vitale; Jennifer E Thorne
Journal:  Am J Ophthalmol       Date:  2011-09-08       Impact factor: 5.258

8.  Testing acuity of vision in general practice: reaching recommended standard.

Authors:  J C Pandit
Journal:  BMJ       Date:  1994-11-26

9.  Measuring visual acuity in general practice. Agreement is needed on what constitutes acceptable primary ophthalmic care.

Authors:  R D Neal; T James
Journal:  BMJ       Date:  1995-03-11

10.  Measuring visual acuity in general practice. May not be reliable.

Authors:  M J Moseley; H S Jones; P I Murray
Journal:  BMJ       Date:  1995-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.